Literature DB >> 15517412

Cyclosporin A does not affect platelets in children with idiopathic nephrotic syndrome.

Marcin Tkaczyk1, Zbigniew Baj, Michał Nowicki.   

Abstract

The immunosuppressive agents administered to maintain the remission of idiopathic nephrotic syndrome (INS) may have a deleterious effect on several cell types. The aim of this study was to analyze platelet activation and reactivity in children with INS treated with cyclosporin A (CyA). The study groups comprised 16 children with remission of INS induced by CyA and 16 children with glucocorticosteroid-induced remission 8 weeks from the onset of INS relapse. Fifteen healthy children served as controls. Surface expression of CD61, CD62P, and CD42b on resting and thrombin-stimulated platelets was analyzed with flow cytometry. No differences between groups were found in CD61, CD62P, and CD42b surface expression, but markers of the coagulation cascade and fibrinolysis or endothelial injury (F1+2 prothrombin fragments, tissue plasminogen activator inhibitor 1) were elevated in patients treated with CyA compared with children on steroids and healthy controls. No correlations between markers of platelet function and CyA concentration were found. We postulate that CyA administration in nephrotic patients causes an activation of thrombinogenesis but does not influence platelet activation and reactivity in INS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15517412     DOI: 10.1007/s00467-004-1674-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  33 in total

Review 1.  Nitric oxide insufficiency, platelet activation, and arterial thrombosis.

Authors:  J Loscalzo
Journal:  Circ Res       Date:  2001-04-27       Impact factor: 17.367

2.  Cyclosporine is associated with endothelial dysfunction but not with platelet activation in renal transplantation.

Authors:  Y C Schrama; T van Dam; R Fijnheer; R J Hené; P de Groot; T J Rabelink
Journal:  Neth J Med       Date:  2001-07       Impact factor: 1.422

3.  Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis.

Authors:  M J Gregory; W E Smoyer; A Sedman; D B Kershaw; R P Valentini; K Johnson; T E Bunchman
Journal:  J Am Soc Nephrol       Date:  1996-04       Impact factor: 10.121

4.  Effects of amlodipine and enalapril on platelet function in patients with mild to moderate hypertension.

Authors:  R Hernández-Hernández; M C Armas-Padilla; M Velasco; A R Carvajal; M J Armas de Hernández; J Guerrero-Pajuelo; B Pacheco
Journal:  Int J Clin Pharmacol Ther       Date:  1999-07       Impact factor: 1.366

5.  Immunosuppressive therapy regimen and platelet activation in renal transplant patients.

Authors:  Jochen Graff; Ute Klinkhardt; Sebastian Harder; Wolfgang Wegert; Tomas Lenz; Ernst-Heinrich Scheuermann; Jan Gossmann
Journal:  Clin Pharmacol Ther       Date:  2002-10       Impact factor: 6.875

6.  Long-term clinical and pathological effects of cyclosporin in children with nephrosis.

Authors:  M G Seikaly; H Prashner; B Nolde-Hurlbert; R Browne
Journal:  Pediatr Nephrol       Date:  2000-03       Impact factor: 3.714

7.  Cyclosporine-induced detachment of vascular endothelial cells initiates the intrinsic coagulation system in plasma and whole blood.

Authors:  T Bombeli; M Müller; P W Straub; A Haeberli
Journal:  J Lab Clin Med       Date:  1996-06

8.  Cyclosporine produces endothelial dysfunction by increased production of superoxide.

Authors:  D Diederich; J Skopec; A Diederich; F X Dai
Journal:  Hypertension       Date:  1994-06       Impact factor: 10.190

9.  Long-term low-dose cyclosporin A in steroid dependent nephrotic syndrome of childhood.

Authors:  T J Neuhaus; H R Burger; M Klingler; A Fanconi; E P Leumann
Journal:  Eur J Pediatr       Date:  1992-10       Impact factor: 3.183

10.  Cyclosporin A augments human platelet sensitivity to aggregating agents by increasing fibrinogen receptor availability.

Authors:  S J Fishman; L J Wylonis; J D Glickman; J J Cook; D S Warsaw; C A Fisher; D J Jorkasky; S Niewiarowski; V P Addonizio
Journal:  J Surg Res       Date:  1991-08       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.